Business context and reporting period
Important filing-identity discrepancy: The request identifies CalciMedica, Inc., but the supplied Form 10-Q is for Graybug Vision, Inc. (Nasdaq: GRAY), for the quarter ended September 30, 2022, filed November 10, 2022. This summary reflects the supplied filing, not a CalciMedica filing.
Graybug was a clinical-stage biotechnology company with no approved products or product revenue. After announcing a strategic review in June 2022, it was evaluating a sale, merger, acquisition, asset divestiture, private equity financing, or other transaction. In August, the company ended activities on GB-102 and GB-401, reduced its workforce by 71%, and continued preclinical work on GB-501 while clinical development remained on hold.
Financial results and position
Amounts below are in millions of dollars, except per-share data. The filing reports no revenue; operating expenses therefore drove the reported losses, and revenue margins are not meaningful.
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Research and development expense | $3.249 | $4.021 | $13.364 | $14.635 |
| General and administrative expense | $4.299 | $3.996 | $12.669 | $12.611 |
| Restructuring, impairment and terminated-program costs | $2.435 | — | $2.435 | — |
| Total operating expenses | $9.983 | $8.017 | $28.468 | $27.246 |
| Net loss | $9.812 | $7.989 | $28.202 | $27.146 |
| Net loss per share, basic and diluted | $0.46 | $0.38 | $1.32 | $1.28 |
| Net cash used in operating activities | Not provided | Not provided | $17.806 | $22.545 |
At September 30, 2022, cash and cash equivalents were $10.170 million and short-term investments were $33.457 million, totaling $43.627 million. Current assets were $45.071 million, current liabilities $3.762 million, and stockholders’ equity $41.599 million. Total liabilities were $3.762 million; the filing reports no debt balance. Accumulated deficit was $197.390 million. Nine-month investing cash inflow was $14.698 million, largely reflecting net maturities of investments; financing cash outflow was $0.086 million.
Material changes versus prior comparable periods
- Q3 operating expenses rose 25% and net loss rose 23% year over year, primarily reflecting $2.435 million of restructuring and impairment costs. R&D expense fell 19% as programs were wound down; G&A increased 8%, mainly due to stock-based compensation.
- For the first nine months, total operating expenses increased 4% and net loss increased 4%. Lower R&D costs were partly offset by the $2.2 million RainBio in-process R&D charge and restructuring costs.
- Cash, cash equivalents and short-term investments declined from $63.670 million at December 31, 2021 to $43.627 million at September 30, 2022. Cash and cash equivalents alone decreased by $3.194 million over the nine-month period.
Outlook, risks and unusual items
- Management said available cash, cash equivalents and short-term investments were expected to fund needs for at least 12 months from the report’s issuance, based on a reduced-spending operating plan. The strategic review could change that plan. The company also said additional funding would be needed to advance programs and operate longer term; no financing was committed, and a strategic transaction or financing was not assured.
- The restructuring charge included $1.309 million of equipment impairment, $1.025 million of severance and termination benefits, and $0.101 million of other costs. The company had 20 affected employees and recorded a $0.538 million severance liability at quarter-end.
- RainBio was acquired in March 2022 for approximately $2.2 million, recorded as R&D expense. Contingent payments of up to $17.5 million may be due upon specified milestones; none were considered probable or accrued at September 30.
- Subsequent to quarter-end, Graybug gave notice terminating its Johns Hopkins University license rights relevant to GB-102 and GB-401. On November 10, 2022, it agreed to return GB-601 intellectual property and rights to Mireca Medicines GmbH in exchange for release of future obligations.
- The company disclosed Nasdaq minimum-bid-price noncompliance notice in June 2022 and reported regaining compliance in July; continued listing remained dependent on share-price and other requirements. It also warned that failure to complete a strategic transaction could lead to further cuts, cessation of development, or a wind-down or liquidation, potentially leaving shareholders with less than market value.
Investor verification priorities
- Confirm the issuer: the supplied filing is Graybug Vision, Inc., not CalciMedica, Inc.
- Reconcile the filing’s cash and investment figures: the financial statements show $43.627 million at September 30, while a risk-factor passage states $50.7 million, which does not match the reported balance sheet.
- Assess the status and outcome of the strategic review, including any transaction, financing, liquidation plan, or subsequent change in cash runway.
- Verify the scope and financial consequences of the GB-102/GB-401 terminations, JHU license termination, GB-601 divestiture, and remaining GB-501/GB-701 work.
- Review the potential $17.5 million RainBio milestone obligations and the remaining contractual, lease, severance, and wind-down commitments.